Department of Medical Affairs & Pharmacovigilance • Clinical Formulary Monograph
D 92/6 Okhla Phase 1, New Delhi, 110020, India • Medical Helpline: +91 11-47532297 • Email: contact@vrmedhealthcare.com
Etoversa-MR
Targeted COX-2 Inhibitor & Spasmolytic Muscle Relaxant
Etoversa-MR
Targeted COX-2 Inhibitor & Spasmolytic Muscle Relaxant
Etoricoxib IP 60mg + Thiocolchicoside IP 4mg
Product Clinical Overview
Etoversa-MR combines Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, with Thiocolchicoside, a semi-synthetic sulfur derivative of colchicoside functioning as a central muscle relaxant. This rational combination provides simultaneous anti-inflammatory analgesia and skeletal muscle spasm relief in acute musculoskeletal conditions.
More Images
Actual Etoversa-MR packaging, label panels and blister strip.
Key Ingredients & Pharmacological Profiles
Active chemical constituents, standardized strengths, and physiological roles.
Selective inhibitor of COX-2 reducing local inflammatory prostaglandin synthesis.
Centrally acting GABA-mimetic and glycinergic spasmolytic muscle relaxant.
Approved Clinical Indications
Clinical contexts where this formulation is prescribed under medical supervision.
Pharmacological Mechanism of Action
Etoricoxib selectively halts prostaglandin production by inhibiting the inducible COX-2 enzyme without interfering with constitutive COX-1 physiological protection. Thiocolchicoside interacts with spinal GABA-A and glycine receptors to decrease motor neuron excitability.
Formulation & Delivery Technology
- Selectively targets COX-2 enzyme at inflammatory sites with reduced GI ulceration risk compared to non-selective NSAIDs
- Thiocolchicoside relieves skeletal hypertonicity through central inhibitory neural pathways
- Film-coated tablets engineered for rapid disintegration and systemic absorption
VR Med Healthcare Pvt. Ltd.
Registered Office & Facility:D 92/6 Okhla Phase 1, New Delhi, 110020, India
Quality Certifications:WHO-GMP Compliant & ISO 9001:2015 Certified
Medical Helpline:+91 11-47532297
Corporate Email:contact@vrmedhealthcare.com
Administration & Packaging Details
1 tablet twice daily after meals, typically for 5 to 7 days, strictly under orthopedic or medical guidance.
10 x 10 Tablets (Alu-Alu Blister)
Store protected from moisture and light at a temperature not exceeding 30°C.
This formulation monograph is published strictly for the professional scientific reference and educational use of Registered Medical Practitioners, Hospitals, and Clinical Laboratories. The technical and pharmacological details presented herein do not constitute medical advice, diagnostic opinion, or therapeutic claims. These products must be prescribed, dispensed, and administered strictly in accordance with local drug regulations and under the supervision of a licensed physician. VR Med Healthcare Pvt. Ltd. does not promote self-medication, off-label usage, or unsolicited consumer health claims.
More in Pain & Muscle
Etoversa-60
Selective COX-2 Inhibitor for Joint & Musculoskeletal Pain
Tremasine
Centrally Acting Opioid & Analgesic-Antipyretic Combination
Vibanuron
Pregabalin with Methylcobalamin Neuropathic Pain Formulation
Enhancing Lives With
Quality Healthcare & Integrity.
VR Med Healthcare has been a trusted benchmark in the Indian pharmaceutical sector since 2010. Headquartered in Okhla Phase 1, New Delhi, our dedicated team of over 100 professionals collaborates with leading physicians and distributors across India to make premium medicines accessible and reliable.
“Our goal is to deliver quality of care in a courteous, respectful, and compassionate manner. We hope you will allow us to care for you and strive to be the first and best choice for healthcare professionals and families.”
Kamal Choudhary
Managing Director, VR Med Healthcare
Established
Approved Formulations
Healthcare Specialists
Manufacturing Standard